You just read:

AbbVie Receives European Commission Approval of RINVOQ™ (upadacitinib) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis

News provided by

AbbVie

Dec 18, 2019, 10:50 ET